Report cover image

Indian Digital Pathology Market, 2026-2035

Published Jan 04, 2026
Length 112 Pages
SKU # ORMR21116678

Description

India Digital Pathology Market Size, Share & Trends Analysis Report by Product (Scanner Device, Software, and Storage System), by Application (Teleconsultation, Disease Diagnosis, Drug Discovery, and Other), and by End-User (Biotechnology & Pharmaceutical Companies, Hospitals, and Others), Forecast Period (2026-2035)

Industry Overview

India digital pathology market was valued at $30.2 million in 2025 and is projected to reach $284.6 million by 2035, growing at a CAGR of 25.2% during the forecast period (2026–2035). The India digital pathology market is witnessing steady growth as healthcare providers increasingly adopt advanced imaging technologies to enhance diagnostic accuracy and efficiency. The rising incidence of chronic and complex diseases has driven hospitals and laboratories to implement high-resolution scanners and integrated software platforms. The government’s initiatives promoting digital health and telemedicine are facilitating the deployment of remote diagnostic and workflow management solutions. Pharmaceutical and biotechnology companies are increasingly leveraging digital pathology for research, drug development, and biomarker analysis. Growing awareness among clinicians regarding AI-assisted diagnostics and automated image analysis is further supporting market expansion. Additionally, investments in cloud-based storage and collaborative platforms are enabling streamlined operations and improved patient care across the country.

Market Dynamics

Expansion of AI-Assisted Diagnostic Solutions

In India, the adoption of AI-powered digital pathology platforms is growing rapidly, driven by the need for faster and more accurate diagnostic workflows. Hospitals and diagnostic centers are implementing image analysis software that automates tissue quantification and supports decision-making in disease diagnosis. Key players such as Leica Biosystems, Philips, and Roche are actively introducing AI-integrated platforms tailored for the Indian market. Cloud-enabled solutions are enhancing remote access and teleconsultation capabilities, particularly in regions with limited pathology infrastructure. Recent trends indicate a strong focus on integrating AI with high-resolution scanners to improve throughput and efficiency. This adoption is expected to continue expanding as awareness of digital pathology benefits increases.

Rising Use of Digital Pathology in Drug Discovery and Research

Digital pathology is increasingly being utilized by pharmaceutical and biotechnology companies in India to accelerate drug development and translational research. High-resolution scanners and advanced software platforms enable biomarker identification, tissue analysis, and multi-site collaboration for clinical studies. Companies like PerkinElmer, Visiopharm, and 3DHISTECH are expanding their offerings to meet the growing demand in research institutions. The trend is further supported by government incentives for R&D and increased investment in laboratory modernization. Cloud-based data storage and secure image sharing are facilitating more efficient workflows and collaboration. This sub-segment is projected to witness rapid growth throughout the forecast period.

Market Segmentation
  • Based on the product, the market is segmented into scanner devices, software, and storage systems.
  • Based on the application, the market is segmented into teleconsultation, disease diagnosis, drug discovery, and other.
  • Based on the end-user, the market is segmented into biotechnology & pharmaceutical companies, hospitals, and others.
Scanner Devices as the Pillar of India’s Digital Pathology Growth

Scanner devices, including whole-slide scanners and high-resolution imaging hardware, dominate India’s digital pathology market as the largest segment. Their widespread adoption is fueled by the need for high-throughput slide digitization in hospitals, diagnostic laboratories, and research centers, especially given the rising prevalence of oncology and chronic diseases. Major global and domestic players are investing heavily to supply advanced scanners tailored for the Indian healthcare ecosystem. Healthcare institutions are seeking faster and more accurate diagnostic workflows, making scanner devices the foundational technology driving the country’s shift toward fully digital pathology solutions.

Software Platforms as the Fastest Growing Driver of Diagnostic Efficiency

Digital pathology software, encompassing AI-powered analytics, image management, cloud-based reporting, and workflow integration, is emerging as the fastest-growing sub-segment in India. Rapid growth is propelled by increasing demand for remote diagnostics, tele-pathology services, and automated slide analysis to enhance diagnostic accuracy. Leading companies are introducing AI-integrated, cloud-ready platforms to streamline pathology operations, reduce reliance on manual interpretation, and accelerate turnaround times. Shortage of trained pathologists and expansion of digital infrastructure are set to transform the efficiency and reach of pathology services across hospitals, laboratories, and research facilities nationwide.

Market Players Outlook

The major companies operating in the India digital pathology market include Leica Biosystems Nussloch GmbH, OptraSCAN Inc., Philips India Ltd., and Roche Products (India) Pvt. Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments
  • In November 2025, KIMS, Odisha, has commissioned the SG60 Digital Pathology Scanner, becoming one of the few Indian institutions to fully integrate digital pathology into routine diagnostics, enhancing cancer diagnosis speed and workflow efficiency. The high-resolution scanner enables rapid slide digitization, automated analysis, and remote collaboration, and lays the groundwork for AI-powered diagnostic services.
  • In March 2023, SRL Diagnostics announced that it had partnered with PathPresenter to enable digital pathology consultations between SRL’s state-of-the-art reference laboratories in Mumbai, Gurugram, and Bengaluru.
The Report Covers
  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the India digital pathology market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

Table of Contents

112 Pages
1. Report Summary
Current Industry Analysis and Growth Potential Outlook
India Digital Pathology Market Sales Analysis – Product Application End-User ($ Million)
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot
2. Market Overview and Insights
2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
2.2.1. Key India Digital Pathology Industry Trends
2.2.2. Market Recommendations
3. Market Determinants
3.1. Market Drivers
3.1.1. Drivers For India Digital Pathology Market: Impact Analysis
3.2. Market Pain Points and Challenges
3.2.1. Restraints For India Digital Pathology Market: Impact Analysis
3.3. Market Opportunities
3.3.1. Opportunities For India Digital Pathology Market: Impact Analysis
4. Competitive Landscape
4.1. Competitive Dashboard – India Digital Pathology Market Revenue and Share
Digital Pathology Product Comparison Analysis
4.2. Key Company Analysis
4.2.1. Leica Biosystems Nussloch GmbH
4.2.1.1. Overview
4.2.1.2. Product Portfolio
4.2.1.3. Financial Analysis
4.2.1.4. SWOT Analysis
4.2.1.5. Business Strategy
4.2.2. OptraSCAN Inc.
4.2.2.1. Overview
4.2.2.2. Product Portfolio
4.2.2.3. Financial Analysis
4.2.2.4. SWOT Analysis
4.2.2.5. Business Strategy
4.2.3. Philips India Ltd.
4.2.3.1. Overview
4.2.3.2. Product Portfolio
4.2.3.3. Financial Analysis
4.2.3.4. SWOT Analysis
4.2.3.5. Business Strategy
4.2.4. Roche Products (India) Pvt. Ltd.
4.2.4.1. Overview
4.2.4.2. Product Portfolio
4.2.4.3. Financial Analysis
4.2.4.4. SWOT Analysis
4.2.4.5. Business Strategy
4.3. Top Winning Strategies by Market Players
4.3.1. Merger and Acquisition
4.3.2. Product Launch
4.3.3. Partnership And Collaboration
5. India Digital Pathology Market Sales Analysis by Product ($ Million)
5.1. Scanner Device
5.2. Software
5.3. Storage System
6. India Digital Pathology Market Sales Analysis by Application ($ Million)
6.1. Teleconsultation
6.2. Disease Diagnosis
6.3. Drug Discovery
6.4. Other
7. India Digital Pathology Market Sales Analysis by End-User ($ Million)
7.1. Biotechnology & Pharmaceutical Companies
7.2. Hospitals
7.3. Others
8. Company Profiles
8.1. 3DHISTECH Ltd.
8.1.1. Quick Facts
8.1.2. Company Overview
8.1.3. Product Portfolio
8.1.4. Business Strategies
8.2. AetherAI
8.2.1. Quick Facts
8.2.2. Company Overview
8.2.3. Product Portfolio
8.2.4. Business Strategies
8.3. Agfa-Gevaert Group
8.3.1. Quick Facts
8.3.2. Company Overview
8.3.3. Product Portfolio
8.3.4. Business Strategies
8.4. Apollo Digital Pathology
8.4.1. Quick Facts
8.4.2. Company Overview
8.4.3. Product Portfolio
8.4.4. Business Strategies
8.5. Fujifilm India Ltd.
8.5.1. Quick Facts
8.5.2. Company Overview
8.5.3. Product Portfolio
8.5.4. Business Strategies
8.6. Hamamatsu Photonics K.K.
8.6.1. Quick Facts
8.6.2. Company Overview
8.6.3. Product Portfolio
8.6.4. Business Strategies
8.7. Ibex Medical Analytics Ltd.
8.7.1. Quick Facts
8.7.2. Company Overview
8.7.3. Product Portfolio
8.7.4. Business Strategies
8.8. Indica Labs LLC.
8.8.1. Quick Facts
8.8.2. Company Overview
8.8.3. Product Portfolio
8.8.4. Business Strategies
8.9. Jeeva Clinical Trials Inc.
8.9.1. Quick Facts
8.9.2. Company Overview
8.9.3. Product Portfolio
8.9.4. Business Strategies
8.10. Leica Biosystems Nussloch GmbH.
8.10.1. Quick Facts
8.10.2. Company Overview
8.10.3. Product Portfolio
8.10.4. Business Strategies
8.11. Metropolis Healthcare Ltd.
8.11.1. Quick Facts
8.11.2. Company Overview
8.11.3. Product Portfolio
8.11.4. Business Strategies
8.12. Morphle Labs Inc.
8.12.1. Quick Facts
8.12.2. Company Overview
8.12.3. Product Portfolio
8.12.4. Business Strategies
8.13. OptraScan Inc.
8.13.1. Quick Facts
8.13.2. Company Overview
8.13.3. Product Portfolio
8.13.4. Business Strategies
8.14. Panacea Medical Technologies Pvt. Ltd
8.14.1. Quick Facts
8.14.2. Company Overview
8.14.3. Product Portfolio
8.14.4. Business Strategies
8.15. PathPresenter Corp
8.15.1. Quick Facts
8.15.2. Company Overview
8.15.3. Product Portfolio
8.15.4. Business Strategies
8.16. Philips India Ltd.
8.16.1. Quick Facts
8.16.2. Company Overview
8.16.3. Product Portfolio
8.16.4. Business Strategies
8.17. Qritive Pte. Ltd.
8.17.1. Quick Facts
8.17.2. Company Overview
8.17.3. Product Portfolio
8.17.4. Business Strategies
8.18. Roche Products (India) Pvt. Ltd.
8.18.1. Quick Facts
8.18.2. Company Overview
8.18.3. Product Portfolio
8.18.4. Business Strategies
8.19. Siemens Healthcare Ltd.
8.19.1. Quick Facts
8.19.2. Company Overview
8.19.3. Product Portfolio
8.19.4. Business Strategies
8.20. SigTuple Technologies Pvt. Ltd.
8.20.1. Quick Facts
8.20.2. Company Overview
8.20.3. Product Portfolio
8.20.4. Business Strategies
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.